India's First Drug EMR Could Set Off Litigation Wave, Industry Warns

Law360, New York (November 13, 2003, 12:00 AM EST) -- The grant of India's first exclusive marketing right (EMR) to Swiss drugmaker Novartis for its leukemia medicine Gilvec (imatinib mesylate) could set off a wave of patent litigation, the Economic Times of India reported.

Novartis' EMR grant, issued by the Controller General of Patents and Trademarks of India, blocks the duplication and sale of the drug by any other company for five years.

"We are in an uncharted territory and we are evaluating all our options carefully. We hope that the Indian government will ensure the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.